Researchers at The University of Manchester have discovered that a potential new drug reduces the number of brain cells destroyed by stroke and then helps to repair the damage.
A reduction in blood flow to the brain caused by stroke is a major cause of death and disability, and there are few effective treatments.
A team of scientists at The University of Manchester has now found that a potential new stroke drug not only works in rodents by limiting the death of existing brain cells but also by promoting the birth of new neurones (so-called neurogenesis).
This finding provides further support for the development of this anti-inflammatory drug, interleukin-1 receptor antagonist (IL-1Ra in short), as a new treatment for stroke. The drug is already licensed for use in humans for some conditions, including rheumatoid arthritis. Several early stage clinical trials in stroke with IL-1Ra have already been completed in Manchester, though it is not yet licensed for this condition.
In the research, published in the biomedical journal Brain, Behavior and Immunity, the researchers show that in rodents with a stroke there is not only reduced brain damage early on after the stroke, but several days later increased numbers of new neurones, when treated with the anti-inflammatory drug IL-1Ra.
Previous attempts to find a drug to prevent brain damage after stroke have proved unsuccessful and this new research offers the possibility of a new treatment.
Importantly, the use of IL-1Ra might be better than other failed drugs in stroke as it not only limits the initial damage to brain cells, but also helps the brain repair itself long-term through the generation of new brain cells.
The results lend further strong support to the use of IL-1Ra in the treatment of stroke, however further large trials are necessary
Professor Stuart Allan
These new cells are thought to help restore function to areas of the brain damaged by the stroke. Earlier work by the same group showed that treatment with IL-1Ra does indeed help rodents regain motor skills that were initially lost after a stroke. Early stage clinical trials in stroke patients also suggest that IL-1Ra could be beneficial.
Learn more: New drug limits and then repairs brain damage in stroke
The Latest on: Stroke treatment
[google_news title=”” keyword=”Stroke treatment” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Stroke treatment
- Stroke, hemorrhage, sepsis: Idaho doctors detail ways abortion ban risks patients’ healthon April 27, 2024 at 5:58 am
Dr. Becky Uranga has always loved working in emergency obstetrics. As an OB-GYN, she and her colleagues at OGA Women’s Health rotate emergency shifts, when Uranga spends 24 hours coveri ...
- FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweighton April 26, 2024 at 9:58 am
The U.S. Food and Drug Administration recently approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with ...
- Do you know the warning signs of a stroke?on April 26, 2024 at 7:45 am
Did you know that strokes are the second most common cause of death in the world? According to the World Health Organization (WHO), they're also the third most common cause of disability. Despite how ...
- Why employers should prioritize stroke prevention in the workplaceon April 25, 2024 at 3:16 pm
A stroke rehabilitation specialist explains the risk factors women face, and how certain lifestyle changes can keep them healthy.
- Mom Gives Birth, Suffers Near-Fatal Stroke Hours Later Due to Undetected Heart Defect: ‘Ticking Time Bomb’on April 25, 2024 at 6:17 am
California native Christina Aleksanian is lucky to be alive after she had a stroke hours after giving birth to her third daughter and was rushed to the operating room where doctors removed a blood ...
- ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatmenton April 24, 2024 at 11:00 pm
Yannick PLETAN, General Manager & Chief Medical Officer, comments: "These results obtained with glenzocimab in combination with the reference stroke treatment are extremely disappointing and in ...
- ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatmenton April 24, 2024 at 11:00 pm
ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of glenzocimab, an innovative drug for the treatment of cardiovascular ...
- Stroke Recovery: A Timelineon April 24, 2024 at 9:00 pm
How much progress a person can make and the timeline for their recovery depend on the type and location of the stroke and the patient’s age and overall health, says Richard Harvey, M.D., clinical ...
- Teleneurology for Suspected Stroke Speeds Treatmenton April 24, 2024 at 6:30 am
Alerting neurologists via telemedicine that a patient with suspected acute stroke is en route to the hospital significantly speeds thrombolytic treatment.
via Bing News